Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP1011T Tablets in Advanced Solid Tumors (Phase IIb, Open-Label, Multi-Cohort)
ChiCTR2500112795Phase 2Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ABP1011T in small cell lung cancer (SCLC), esophageal cancer, Cervical Cancer (CC) and 4 more (2 cohorts), sponsored by Shanghai East Hospital. Primary endpoint: Objective response rate (ORR) – primary. Started Nov 2025; status: recruiting.
02
Drugs
ABP1011T
03
Conditions
small cell lung cancer (SCLC)esophageal cancerCervical Cancer (CC)bladder cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2500112795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112795.